Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

被引：0

作者：

Weisel, K. ^{[1
]}

Palumbo, A. ^{[2
]}

Chanan-Khan, A. ^{[3
]}

Nooka, A. K. ^{[4
]}

Spicka, I. ^{[5
]}

Masszi, T. ^{[6
]}

Beksac, M. ^{[7
]}

Hungria, V. ^{[8
]}

Munder, M. ^{[9
]}

Mateos, M-V. ^{[10
]}

Mark, T. M. ^{[11
]}

Spencer, A. ^{[12
]}

Qi, M. ^{[13
]}

Schecter, J. ^{[14
]}

Amin, H. ^{[14
]}

Qin, X. ^{[15
]}

Deraedt, W. ^{[16
]}

Ahmadi, T. ^{[13
]}

Sonneveld, P. ^{[17
]}

机构：

[1] Eberhard Karls Univ Tubingen, Univ Klinikum Tuebingen, Dept Hematol Oncol Immunol Rheumatol & Pulmonol, Abt Innere Med 2, Tubingen, Germany

[2] Univ Turin, Dept Hematol, Turin, Italy

[3] Mayo Clin Florida, Div Hematol & Med Oncol, Jacksonville, FL USA

[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[5] Charles Univ Prague, Med Dept 1, Dept Clin Haematol, Prague, Czech Republic

[6] Semmelweis Univ, St Laszlo Hosp, Dept Haematol & Stem Cell Transplantat, Budapest, Hungary

[7] Ankara Univ, Dept Hematol, Ankara, Turkey

[8] Irmandade Santa Casa De Misericordia Sao Paulo, Sao Paulo, Brazil

[9] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany

[10] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[11] Weill Cornell Med Coll, New York, NY USA

[12] Monash Univ, Malignant Haematol & Stem Cell Transplantat Serv, Alfred Hlth, Melbourne, Vic, Australia

[13] Janssen Res & Dev LLC, Spring House, PA USA

[14] Janssen Res & Dev LLC, Raritan, NJ USA

[15] Janssen Res & Dev LLC, Horsham, PA USA

[16] Janssen Res & Dev, Beerse, Belgium

[17] Erasmus MC, Dept Hematol, Rotterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw375.1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

906O

引用

页数：1

共 50 条

[31] Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Katja Weisel
Andrew Spencer
Suzanne Lentzsch
Hervé Avet-Loiseau
Tomer M. Mark
Ivan Spicka
Tamas Masszi
Birgitta Lauri
Mark-David Levin
Alberto Bosi
Vania Hungria
Michele Cavo
Je-Jung Lee
Ajay Nooka
Hang Quach
Markus Munder
Cindy Lee
Wolney Barreto
Paolo Corradini
Chang-Ki Min
Asher A. Chanan-Khan
Noemi Horvath
Marcelo Capra
Meral Beksac
Roberto Ovilla
Jae-Cheol Jo
Ho-Jin Shin
Pieter Sonneveld
Tineke Casneuf
Nikki DeAngelis
Himal Amin
Jon Ukropec
Rachel Kobos
Maria-Victoria Mateos
Journal of Hematology & Oncology, 13
[32] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Lonial, Sagar
Richardson, Paul G.
Popat, Rakesh
Stadtmauer, Edward A.
Larsen, Jeremy T.
Oriol, A.
Knop, Stefan
Jagannath, Sundar
Cook, Gordon
Badros, Ashraf Z.
Rodriguez-Otero, Paula
Siegel, David S.
Nguyen, Tuong Vi
Di Micco, Antonia
Amin, Alpesh
Chen, Min
Kueenburg, Elisabeth
van de Donk, Niels W. C. J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S9 - S9
[33] Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
Pour, Ludek
Efebera, Yvonne
Granell, Miquel
Hajek, Roman
Oriol, Albert
Delaunay, Jacques
Le Du, Katell
Eveillard, Jean-Richard
Karlin, Lionel
Maisnar, Vladimir
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Moreb, Jan
Ribrag, Vincent
Richardson, Paul G.
Straub, Jan
Byrne, Catriona
Jacques, Christian
Zubair, Hanan
Ocio, Enrique
CANCER RESEARCH, 2019, 79 (13)
[34] Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor
Chanan-Khan, Asher A.
Lentzsch, Suzanne
Quach, Hang
Horvath, Noemi
Capra, Marcelo
Ovilla, Roberto
Jo, Jae-Cheol
Shin, Ho-Jin
Qi, Ming
Deraedt, William
Schecter, Jordan
Amin, Himal
Qin, Xiang
Casneuf, Tineke
Chiu, Christopher
Sasser, A. Kate
Sonneveld, Pieter
BLOOD, 2016, 128 (22)
[35] Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng
H Goldschmidt
M A Dimopoulos
P Moreau
D Joshua
A Palumbo
T Facon
H Ludwig
L Pour
R Niesvizky
A Oriol
L Rosiñol
A Suvorov
G Gaidano
T Pika
K Weisel
V Goranova-Marinova
H H Gillenwater
N Mohamed
S Feng
S Aggarwal
R Hájek
Leukemia, 2017, 31 : 1368 - 1374
[36] CARFILZOMIB AND DEXAMETHASONE (KD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN PATIENTS (PTS) WITH MULTIPLE MYELOMA IN RELAPSE (MMR): RESULTS OF THE STUDY OF PHASE 3 ENDEAVOR
Oriol, A.
Rosinol, L.
Dimopoulos Meletios, A.
Moreau, P.
Palumbo, A.
Joshua, D.
Pour, L.
Hajek, R.
Facon, T.
Ludwig, H.
Goldschmidt, H.
Straub, J.
Suvorov, A.
Araujo, C.
Andreeva, N.
Pika, T.
Gaidano, G.
Weisel, K.
Gillenwater, H.
Chng, W-J
HAEMATOLOGICA, 2015, 100 : 41 - 41
[37] Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor
Mateos, Maria-Victoria
Estell, Jane
Barreto, Wolney
Corradini, Paolo
Min, Chang-Ki
Medvedova, Eva
Qi, Ming
Schecter, Jordan
Amin, Himal
Qin, Xiang
Deraedt, William
Casneuf, Tineke
Chiu, Christopher
Sasser, A. Kate
Nooka, Ajay
BLOOD, 2016, 128 (22)
[38] Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.
Weisel, Katja
Spencer, Andrew
Lentzsch, Suzanne
Avet-Loiseau, Herve
Mark, Tomer M.
Spicka, Ivan
Bosi, Alberto
Hungria, Vania T. M.
Cavo, Michele
Lee, Je-Jung
Nooka, Ajay K.
Quach, Hang
Munder, Markus
Beksac, Meral
Sonneveld, Pieter
Soong, David
Ukropec, Jon
Qi, Ming
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[39] Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.
Dimopoulos, Meletios A.
Moreau, Philippe
Palumbo, Antonio
Joshua, Douglas E.
Pour, Ludek
Hajek, Roman
Facon, Thierry
Ludwig, Heinz
Oriol, Albert
Goldschmidt, Hartmut
Rosinol, Laura
Straub, Jan
Suvorov, Aleksandr
Araujo, Carla
Pika, Tomas
Gaidano, Gianluca
Weisel, Katja
Goranova-Marinova, Vesselina
Gillenwater, Heidi H.
Chng, Wee Joo
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Jakubowiak, Andrzej J.
Offidani, Massimo
Pegourie, Brigitte
De La Rubia, Javier
Garderet, Laurent
Laribi, Kamel
Bosi, Alberto
Marasca, Roberto
Laubach, Jacob
Mohrbacher, Ann
Carella, Angelo Michele
Singhal, Anil K.
Tsao, Claire
Lynch, Mark John
Bleickardt, Eric W.
Jou, Ying-Ming
Palumbo, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →